Abstract
Depressive disorders, are not only common but also among the leading causes of disability worldwide. They are associated with increased incidences of various other diseases. It has been shown that in patients with autoimmune diseases, when depression coexists, the quality of life is worse and medical treatment and management is compromised. Depression-like symptoms, such as fatigue and disinterest are also common in inflammatory rheumatic diseases and often associated with poor quality of life. Medical therapy targeting inflammation results in alleviation of these symptoms in many patients. Interestingly, there is cumulating evidence suggesting potential roles of inflammatory cytokines in the pathogenesis of major depression. Effects of some of the biological agents used in rheumatic diseases have been studied on depressive disorders. Results have been controversial and further studies are needed in this area. These findings suggest associations between depression and inflammatory rheumatic diseases and raise the possibility that treatment of one of them might influence the outcome of the other. We have reviewed the current literature on associations between depression and inflammatory rheumatologic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and ankylosing spondylitis.
Keywords: Depression, Inflammation, Rheumatic, Rheumatoid arthritis, Systemic lupus erythematosus, Ankylosing spondylitis, Sjögren's syndrome.
Current Topics in Medicinal Chemistry
Title:Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Volume: 18 Issue: 16
Author(s): Özkan Varan, Hakan Babaoğlu and Berna Göker*
Affiliation:
- Department of Internal Medicine-Rheumatology, Faculty of Medicine, Gazi University, Ankara,Turkey
Keywords: Depression, Inflammation, Rheumatic, Rheumatoid arthritis, Systemic lupus erythematosus, Ankylosing spondylitis, Sjögren's syndrome.
Abstract: Depressive disorders, are not only common but also among the leading causes of disability worldwide. They are associated with increased incidences of various other diseases. It has been shown that in patients with autoimmune diseases, when depression coexists, the quality of life is worse and medical treatment and management is compromised. Depression-like symptoms, such as fatigue and disinterest are also common in inflammatory rheumatic diseases and often associated with poor quality of life. Medical therapy targeting inflammation results in alleviation of these symptoms in many patients. Interestingly, there is cumulating evidence suggesting potential roles of inflammatory cytokines in the pathogenesis of major depression. Effects of some of the biological agents used in rheumatic diseases have been studied on depressive disorders. Results have been controversial and further studies are needed in this area. These findings suggest associations between depression and inflammatory rheumatic diseases and raise the possibility that treatment of one of them might influence the outcome of the other. We have reviewed the current literature on associations between depression and inflammatory rheumatologic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and ankylosing spondylitis.
Export Options
About this article
Cite this article as:
Varan Özkan, Babaoğlu Hakan and Göker Berna *, Associations between Depressive Disorders and Inflammatory Rheumatic Diseases, Current Topics in Medicinal Chemistry 2018; 18 (16) . https://dx.doi.org/10.2174/1568026618666180516100805
DOI https://dx.doi.org/10.2174/1568026618666180516100805 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Patient Attitudes Toward Western Medicine and the Future of Chinese Medicine for Spondyloarthritis
Current Rheumatology Reviews Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety The Prevalence and Significance of Uveitis in Ankylosing Spondylitis and Other Spondyloarthropathies
Current Rheumatology Reviews Ankylosing Spondylitis and Risk of Cardiac Arrhythmia and Conduction Disorders: A Systematic Review and Meta-analysis
Current Cardiology Reviews Formulation and in-vitro Evaluation of a Bilayer Matrix Tablet Containing Aceclofenac as Sustained Release and Paracetamol as Immediate Release
Drug Delivery Letters No Association of MicroRNA-146a rs2910164 Polymorphism and Risk of Primary Gout Development in Chinese Han Populations: A Case-control Study
Current Rheumatology Reviews Ankylosing Spondylitis and Pregnancy: A Literature Review
Current Rheumatology Reviews The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects
Drug Metabolism Letters Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials Antagonizing IL-6 in Ankylosing Spondylitis: A Short Review
Inflammation & Allergy - Drug Targets (Discontinued) Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept
Current Rheumatology Reviews Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)
Current Rheumatology Reviews Innate Immune System Modulation During Aging: Contributions of Macrophages and Dendritic Cells
Current Immunology Reviews (Discontinued) Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery Pro-Inflammatory Cytokines: New Potential Therapeutic Targets for Obesity-Related Bone Disorders
Current Drug Targets Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease
Current Drug Metabolism